Treatment of Hospital-Acquired Pneumonia and Aspiration Pneumonia

Introduction to Appropriate Treatment Regimens

The Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) recommend against using doxycycline for hospital-acquired pneumonia (HAP) treatment due to its inadequate coverage against primary HAP pathogens, including Pseudomonas aeruginosa, other gram-negative bacilli, and methicillin-resistant Staphylococcus aureus (MRSA) 1
The IDSA/ATS guidelines suggest piperacillin-tazobactam as a suitable option for HAP treatment, providing comprehensive coverage for Pseudomonas aeruginosa and other gram-negative bacilli, making additional doxycycline redundant 1

For HAP without high mortality risk, the IDSA/ATS recommend piperacillin-tazobactam 4.5 grams IV every 6 hours as monotherapy, or alternative single agents such as cefepime, ceftazidime, imipenem, or meropenem 1
For HAP with high mortality risk or prior antibiotic use, the IDSA/ATS suggest piperacillin-tazobactam 4.5 grams IV every 6 hours plus a second antipseudomonal agent from a different class, such as a fluoroquinolone or aminoglycoside 1

The IDSA/ATS recommend beta-lactam/beta-lactamase inhibitor monotherapy, such as ampicillin-sulbactam or piperacillin-tazobactam, as first-line therapy for aspiration pneumonia 2
For severe aspiration pneumonia or ICU patients, piperacillin-tazobactam 4.5 grams IV every 6 hours provides adequate coverage for typical pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, and oral anaerobes 2

The IDSA/ATS advise against routinely adding specific anaerobic coverage for aspiration pneumonia unless lung abscess or empyema is present 2
The American College of Clinical Pharmacy and the IDSA recommend against using aminoglycosides as the sole antipseudomonal agent, as they should only be used in combination with a beta-lactam 1
The IDSA/ATS suggest adding MRSA coverage, such as vancomycin or linezolid, only if specific risk factors are present, including prior IV antibiotic use within 90 days or treatment in a unit with high MRSA prevalence 1, 2

The IDSA/ATS recommend a standard treatment duration of 7 days for patients with good clinical response and resolution of clinical features, and up to 10-14 days for severe infections with septic shock or slower clinical improvement 1, 2